Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 1
1927 1
1929 1
1941 2
1943 2
1945 1
1946 4
1947 7
1948 2
1949 4
1950 7
1951 2
1953 3
1954 5
1955 7
1956 3
1957 6
1958 6
1959 10
1960 10
1961 6
1962 12
1963 14
1964 17
1965 20
1966 38
1967 41
1968 40
1969 52
1970 62
1971 52
1972 77
1973 54
1974 81
1975 221
1976 229
1977 231
1978 272
1979 259
1980 344
1981 351
1982 410
1983 521
1984 541
1985 621
1986 664
1987 794
1988 850
1989 1026
1990 1069
1991 1258
1992 1312
1993 1344
1994 1616
1995 1804
1996 1835
1997 2064
1998 2395
1999 2480
2000 2727
2001 3048
2002 3210
2003 3690
2004 4262
2005 4762
2006 5209
2007 5622
2008 6183
2009 6453
2010 7357
2011 7940
2012 8756
2013 9522
2014 10160
2015 10652
2016 11119
2017 11401
2018 12021
2019 12416
2020 13636
2021 14638
2022 14654
2023 14290
2024 14414
2025 16068
2026 8698
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244,284 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean switch OR switch over OR changeover (244,012 results)?
Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience.
Dorling M, Sarafan M, Voizard B, Ammar YA, Hernaiz-Leonardo JC, Chalmers K, MacInnis P, Nugent J, Janjua A, Javer A, Sommer D, Lee J, Chan Y, Thamboo A. Dorling M, et al. Int Forum Allergy Rhinol. 2025 Feb;15(2):166-173. doi: 10.1002/alr.23466. Epub 2024 Oct 18. Int Forum Allergy Rhinol. 2025. PMID: 39422074 Free PMC article.
RESULTS: Note that 225 consecutive patients were included. Thirty-six (16%) switched biologics at least once, and six (3%) switched twice. The most common switch was from mepolizumab to dupilumab, with poor control of CRSwNP symptoms being the leading cause f …
RESULTS: Note that 225 consecutive patients were included. Thirty-six (16%) switched biologics at least once, and six (3%) switche …
Switching disease-modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes.
Belančić A, Gkrinia EMM, Eustaquio P, Faour AK, Vitezić D. Belančić A, et al. Br J Clin Pharmacol. 2025 Jun 19. doi: 10.1002/bcp.70145. Online ahead of print. Br J Clin Pharmacol. 2025. PMID: 40538117 Review.
With multiple disease-modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are d …
With multiple disease-modifying therapies now available, treatment switching has become an important clinical consideration in the ma …
Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors.
Haddad A, Stein N, Feldhamer I, Cohen AD, Saliba W, Zisman D. Haddad A, et al. Semin Arthritis Rheum. 2025 Aug;73:152737. doi: 10.1016/j.semarthrit.2025.152737. Epub 2025 Apr 17. Semin Arthritis Rheum. 2025. PMID: 40267668 Free article.
Patterns of switching were stratified by the number of switches and study periods (2005-2014, 2015-2023). RESULTS: Among 3851 patients initiating bDMARDs, 1848 (48 %) switched therapy at least once. Anti-TNF therapy was the dominant first-line choice, but …
Patterns of switching were stratified by the number of switches and study periods (2005-2014, 2015-2023). RESULTS: Among 3851 …
Switching TNFalpha inhibitors: Patterns and determinants.
Meijboom RW, Gardarsdottir H, Becker ML, de Groot MCH, Movig KLL, Kuijvenhoven J, Egberts TCG, Leufkens HGM, Giezen TJ. Meijboom RW, et al. Pharmacol Res Perspect. 2021 Aug;9(4):e00843. doi: 10.1002/prp2.843. Pharmacol Res Perspect. 2021. PMID: 34302442 Free PMC article.
The aim of this study was to assess switching patterns and determinants for switching in patients initiating TNFalpha inhibitor (TNFalpha-i) treatment. Patients were included who started TNFalpha-i treatment between July 1, 2012 and December 31, 2017, from three Dut …
The aim of this study was to assess switching patterns and determinants for switching in patients initiating TNFalpha inhibito …
Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.
Adelakun AR, Turgeon RD, De Vera MA, McGrail K, Loewen PS. Adelakun AR, et al. BMJ Open. 2023 Apr 25;13(4):e071907. doi: 10.1136/bmjopen-2023-071907. BMJ Open. 2023. PMID: 37185198 Free PMC article.
Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and patients were often censored after the first switch. ...There are aspects of OAC switching that have received little study, espe …
Patients on DOAC switched more to warfarin than to other DOACs. OAC doses involved in the switches were hardly reported and pa …
Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Reynolds MW, et al. J Med Econ. 2010 Mar;13(1):90-8. doi: 10.3111/13696990903579501. J Med Econ. 2010. PMID: 20078189 Free article.
The non-pharmacy medical costs in the 18 months following switching or discontinuation were compared to the costs in a randomly selected similar period for those patients who did not switch or discontinue these agents. ...Non-pharmaceutical medical costs were highes …
The non-pharmacy medical costs in the 18 months following switching or discontinuation were compared to the costs in a randomly selec …
Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor-based antiretroviral regimens.
Chuo CY, Christoph MJ, Zachry W, de Boer M, Chen M, Trom C. Chuo CY, et al. J Med Econ. 2025 Dec;28(1):1241-1251. doi: 10.1080/13696998.2025.2536422. Epub 2025 Aug 4. J Med Econ. 2025. PMID: 40677000 Free article.
The majority of INSTI-based regimen initiations were for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (61%; n = 17,917), followed by dolutegravir/lamivudine (27.4%; n = 8034) and cabotegravir + rilpivirine (7.4%; n = 2186). A subsequent switch occurred in 3341 …
The majority of INSTI-based regimen initiations were for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (61%; n = 17,917), follow …
Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes.
Candido R, Gaiotti S, Giudici F, Toffoli B, De Luca F, Velardi V, Petrucco A, Gottardi C, Manca E, Buda I, Fabris B, Bernardi S. Candido R, et al. J Clin Med. 2023 Sep 19;12(18):6052. doi: 10.3390/jcm12186052. J Clin Med. 2023. PMID: 37762991 Free PMC article.
The median follow-up was 6 months. Be it as a switchover or as an add-on therapy, oral semaglutide significantly reduced HbA1c and BMI. Switching from DPPIV inhibitors to oral semaglutide was associated with a significant reduction in HbA1c and BMI, switching …
The median follow-up was 6 months. Be it as a switchover or as an add-on therapy, oral semaglutide significantly reduced HbA1c and BM …
Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel diseases: results from the Italian VALORE network.
Pellegrini G, Spini A, Bellitto C, L'Abbate L, Ingrasciotta Y, Soardo F, Leoni O, Mazzone A, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Ledda S, Carta P, Rossi P, Ejlli L, Sapigni E, Puccini A, Scarpelli RF, De Sarro G, Tuccori M, Gini R, Allotta A, Addario Pollina S, Da Cas R, Bucaneve G, Mangano AMP, Balducci F, Sorrentino C, Senesi I, Bernardi FF, Trama U, Spila Alegiani S, Mayer F, Massari M, Savarino EV, Variola A, Trifirò G. Pellegrini G, et al. Ther Adv Gastroenterol. 2025 Sep 28;18:17562848251378080. doi: 10.1177/17562848251378080. eCollection 2025. Ther Adv Gastroenterol. 2025. PMID: 41030293 Free PMC article.
TNF-alpha drugs were more likely to switch or swap. They also swapped or switched more rapidly than vedolizumab and ustekinumab. ...We found that treatment switches are common: 12% of patients switched drugs within a year, 36% within three years, and 5 …
TNF-alpha drugs were more likely to switch or swap. They also swapped or switched more rapidly than vedolizumab and ustekinuma …
Does code-switching influence novel word learning?
Kaushanskaya M, Crespo K, Neveu A. Kaushanskaya M, et al. Dev Sci. 2023 Mar;26(2):e13292. doi: 10.1111/desc.13292. Epub 2022 Jun 11. Dev Sci. 2023. PMID: 35639763 Free PMC article.
Code-switching occurs regularly in the input to bilingual children. Yet, the effect of code-switched input on language development is unclear. ...Children required fewer exposures to retain novel words in the code-switch than the English-only condition and th …
Code-switching occurs regularly in the input to bilingual children. Yet, the effect of code-switched input on language develop …
244,284 results
You have reached the last available page of results. Please see the User Guide for more information.